Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Texas MPN Workshop (TMW) 3rd Annual Meeting was held in San Antonio, Texas, from August 26-27. This meeting brought together leading experts in the field of MPNs to discuss recent research, novel therapeutic agents, and updates in the treatment of MPNs.
View all videos

Texas MPN Workshop 2022

The TMW 3rd Annual Workshop and Meeting
26–27 August 2022 | San Antonio, Texas / Online

Texas MPN Workshop 2022

The TMW 3rd Annual Workshop and Meeting
26–27 August 2022 | San Antonio, Texas / Online
The Texas MPN Workshop (TMW) 3rd Annual Meeting was held in San Antonio, Texas, from August 26-27. This meeting brought together leading experts in the field of MPNs to discuss recent research, novel therapeutic agents, and updates in the treatment of MPNs.
View all videos

Presentations

View all
COVID-19 and MPNs: updates from the ELN study
Tiziano Barbui • 10 Nov 2022
Clinical risk factors for disease progression in MPNs
Andrew Kuykendall • 10 Nov 2022
Thrombosis and COVID-19 in MPN patients
Valerio De Stefano • 10 Nov 2022
Mitigating COVID-19 infection risk for MPN patients
Laura Michaelis • 10 Nov 2022

Watch all videos

View all
1:53
The role of chronic inflammation in clonal hematopoiesis and the development of MDS
Rafael Bejar • 26 Aug 2022
1:32
The role of the innate immune system in MDS pathogenesis
Rafael Bejar • 26 Aug 2022
6:37
Drivers of progression in MPNs and the importance of early intervention
Andrew Kuykendall et al. • 26 Aug 2022
1:44
The promise of parsaclisib in patients with MF who have a suboptimal response to JAKi therapy
Srdan Verstovsek • 27 Aug 2022

Myelofibrosis

View all
1:53
The role of chronic inflammation in clonal hematopoiesis and the development of MDS
Rafael Bejar • 26 Aug 2022
1:32
The role of the innate immune system in MDS pathogenesis
Rafael Bejar • 26 Aug 2022
6:37
Drivers of progression in MPNs and the importance of early intervention
Andrew Kuykendall et al. • 26 Aug 2022
1:44
The promise of parsaclisib in patients with MF who have a suboptimal response to JAKi therapy
Srdan Verstovsek • 27 Aug 2022

PV and ET

View all
1:15
Unmet needs and emerging options for patients with PV
Aaron Gerds • 24 Aug 2022
2:15
Advances in the risk stratification and treatment of essential thrombocythemia
Srdan Verstovsek • 27 Aug 2022
1:39
Upcoming agents in ET and PV
Ruben Mesa • 26 Aug 2022
1:12
Unmet needs in ET and future considerations
Aaron Gerds • 24 Aug 2022

Rare and overlap syndromes

View all
2:56
Insights into the treatment and management of advanced systemic mastocytosis
Deepti Radia • 30 Aug 2022
2:18
Insights into the diagnosis and prognosis of CMML
Eric Padron • 26 Aug 2022
1:46
Unmet needs and challenges in advanced systemic mastocytosis
Deepti Radia • 30 Aug 2022
1:16
Tagraxofusp: a promising agent for the treatment of pediatric BPDCN
Naveen Pemmaraju • 27 Aug 2022
The content of VJHemOnc is intended for healthcare professionals